Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Article Type

    Promising Effects of Traditional Chinese Medicines and Isolated Compounds Against SARS-CoV-2

    wadmin1By wadmin1October 8, 2021Updated:October 8, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    I.E.Cock1,2,*
    1School of Natural Sciences, Nathan Campus, Griffith University, Nathan, Brisbane, Queensland, AUSTRALIA.
    2Centre for Planetary Health and Food Security, Nathan Campus, Griffith University, Nathan, Brisbane, Queensland, AUSTRALIA.
    DOI: 10.5530/pc.2021.4.42

    Traditional Chinese Medicine (TCM) was used effectively to treat previous coronavirus outbreaks with minimal side-effects and several TCMs have been highlighted as potential treatments for COVID-19. In particular, Glycyrrhiza glabra L. has been highlighted as useful for decreasing the disease severity in infected people.1 A recent study published in Pharmacognosy Journal utilised in silico prediction based on crystal structures and molecular docking techniques to highlight other promising phytochemicals.2 More than 12,000 compounds were highlighted as potential Mpro inhibitors, with the most promising being Aster pentapeptide A, salvianolic acid B, and ligustrazine. The plant species Zingiberis rhizoma, Asteris radix, Notoginseng radix, Ligusticum chuanxiong, Salviae miltiorrhizae, Zingiberis rhizoma, Dianthi herba, and Cistanches herba were also considered promising. Additionally, gingerketophenol, ginkgol alcohol and ferulic acid were identified as promising ACE2 inhibitors. The plant species Codonopsis radix, This occasional section within the journal surveys visions and achievements, often not on the main track of the developing biomedical sciences, but all relating to discoveries and developments of medicinal – both ancient and modern. What they have in common, in one way or another, is providing further background and glances around the edges of the core discipline of pharmacognosy, as it has been and continues to evolve within our times. Notopterygii rhizoma, Zingiberis rhizoma, Ginkgo semen, Chuanxiong rhizoma, Trichosanthis fructus, Paeoniae radix, Psoraleae fructus, Sophorae flavescentis, Notoginseng radix and Angelicae sinensis also showed good ACE2 inhibitory activity. However, the authors cautioned against indiscriminant usage of any of these medicines as they may have significant toxic effects at therapeutic concentrations. However, the study is useful as it predicted 106 compounds from TCMs that have potential in the treatment of COVID-19.Read more….

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up